Default: Cancer Treatment Reviews

ISSN: 0305-7372

Journal Home

Journal Guideline

Cancer Treatment Reviews Q1 Unclaimed

W.B. Saunders Ltd United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Cancer Treatment Reviews is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 133. It has an SJR impact factor of 4,278 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 4,278.

Cancer Treatment Reviews focuses its scope in these topics and keywords: breast, clinical, kinase, molecular, metastatic, mesotheliomavariability, mechanism, management, malignant, inhibitors, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy:

Type of publications:

Publication frecuency: -

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Cancer Treatment Reviews

4,278

SJR Impact factor

133

H Index

106

Total Docs (Last Year)

345

Total Docs (3 years)

9562

Total Refs

3732

Total Cites (3 years)

341

Citable Docs (3 years)

11,06

Cites/Doc (2 years)

90,21

Ref/Doc

Aims and Scope


breast, clinical, kinase, molecular, metastatic, mesotheliomavariability, mechanism, management, malignant, inhibitors, nm, oncology, overcome, parp, pleural, practice, preclinical, progress, protein, inhibitor, inhibitiondocetaxel, herpositive, biomarkers, cancera, cancerexploitation, cancersthe, cell, checkpoint, combined, cycle, bioavailability, developmentprognostic, drug, established, factors, fork, future,



Best articles by citations

Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer

View more

The potential of melanoma antigen expression in cancer therapy

View more

Thomas Hodgkin and the museum at Guy's Hospital

View more

Thomas Hodgkin remembered

View more

The sentinel node negative axilla: Is it a no-go zone?

View more

Assessment of response to systemic therapy focusing on metastatic bone disease

View more

Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review

View more

A new look at the original cases of Hodgkin's disease

View more

Letter to the editor

View more

Hereditary nonpolyposis colorectal cancer: preventive management

View more

Evidence-based oncology mitomycin C provides little additional benefit in the treatment of carcinoma of unknown primary site

View more

Genetically modified tumour vaccines -where we are today

View more
SHOW MORE ARTICLES

The management of Hodgkin's disease

View more

Clinical effectiveness of radiotherapy for Hodgkin's lymphoma: a summary .

View more

Clinical effectiveness of radiotherapy for non-Hodgkin's lymphoma: a summary

View more

Oral antibiotic administration and early hospital discharge is a safe and effective alternative for treatment of low-risk neutropenic fever

View more

The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy

View more

Breast cancer risk following irradiation for Hodgkin's disease

View more

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues

View more

Photodynamic therapy significantly improves survival outcomes in people with non-resectable cholangiocarcinoma

View more

The current status of FDG-PET in tumour volume definition in radiotherapy treatment planning

View more

Twenty-five years of reviewing cancer treatment

View more

Screening Hodgkin lymphoma survivors for radiotherapy induced cardiovascular disease

View more

Immunotherapy: the last 25 years

View more

Comments

No comments ... Be the first to comment!

FAQS